# A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

> **NCT00136591** · PHASE2 · TERMINATED · sponsor: **Lymphoma Study Association** · enrollment: 87 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00136591
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** An arm closed due to lack of efficacy
- **Last updated:** 2010-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136591, "A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00136591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*